Portal de Periódicos da CAPES

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer

2010; National Academy of Sciences; Volume: 107; Issue: 22 Linguagem: Inglês

10.1073/pnas.0907011107

1091-6490

Sherene Loi, Benjamin Haibe‐Kains, Samira Majjaj, Françoise Lallemand, Virginie Durbecq, Denis Larsimont, Ana M. González-Angulo, Lajos Pusztai, W. Fraser Symmans, Alberto Bardelli, Peter Ellis, Andrew Tutt, Cheryl Gillett, Bryan T. Hennessy, Gordon B. Mills, Wayne A. Phillips, Martine Piccart, Terence P. Speed, Grant A. McArthur, Christos Sotiriou,

Advanced Breast Cancer Therapies

PIK3CA mutations are reported to be present in approximately 25% of breast cancer (BC), particularly the estrogen receptor–positive (ER+) and HER2-overexpressing (HER2+) subtypes, making them one of the most common genetic aberrations in BC. In experimental models, these mutations have been shown to activate AKT and induce oncogenic transformation, and hence these lesions have been hypothesized to render tumors highly sensitive to therapeutic PI3K/mTOR inhibition. By analyzing gene expression and protein data from nearly 1,800 human BCs, we report that a PIK3CA mutation–associated gene signature ( PIK3CA -GS) derived from exon 20 (kinase domain) mutations was able to predict PIK3CA mutation status in two independent datasets, strongly suggesting a characteristic set of gene expression–induced changes. However, in ER+/HER2− BC despite pathway activation, PIK3CA mutations were associated with a phenotype of relatively low mTORC1 signaling and a good prognosis with tamoxifen monotherapy. The relationship between clinical outcome and the PIK3CA -GS was also assessed. Although the PIK3CA -GS was not associated with prognosis in ER− and HER2+ BC, it could identify better clinical outcomes in ER+/HER2− disease. In ER+ BC cell lines, PIK3CA mutations were also associated with sensitivity to tamoxifen. These findings could have important implications for the treatment of PIK3CA -mutant BCs and the development of PI3K/mTOR inhibitors.